Skip to main content
XPOF
NYSE Trade & Services

Fund 1 Proposes Take-Private of Xponential at $5.61-$7.00 Per Share

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Travel & Leisure Stocks · Consumer
Sentiment info
Positive
Importance info
9
Price
$4.48
Mkt Cap
$219.651M
52W Low
$3.565
52W High
$9.25
52W Position info
26% above low
Off High info
52% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

XPOF sits 26% above its 52-week low of $3.565 on elevated volume (1.9× avg).

Summary

Fund 1 Investments proposed a non-binding cash take-private of Xponential at $5.61-$7.00 per share, at least 50% above the $3.74 close on October 29, while holding roughly 19.9% economic exposure.


Key Events · M&A and Partnerships · XPOF

  • Take-Private Proposal Delivered

    Fund 1 sent the board a non-binding proposal to acquire all outstanding Class A shares for $5.61 to $7.00 per share in cash.

  • Premium to Prior Close

    The range is at least 50% above the $3.74 closing price on October 29, 2026, versus a $6.76 price on April 6 when the strategic review began.

  • Fund 1 Holds ~19.9% Exposure

    Fund 1 reports 4,170,610 shares (~9.9%) plus cash-settled total return swaps on 4,213,826 notional shares (~9.98%).

  • Conditions and Poison Pill Waiver

    The bid requires board approval, due diligence and financing, though Fund 1 says definitive agreements would carry no financing condition; it would seek a waiver of the October 12, 2026 Stockholder Rights Agreement.


Analysis · XPOF · Trade & Services

A cash take-private proposal at $5.61-$7.00 per share is now on the table from activist Fund 1, which already holds roughly 19.9% economic exposure. The range sits at least 50% above the $3.74 close on October 29, reframing a stock that has fallen from $6.76 on April 6, when the company began a strategic review, and giving shareholders a concrete floor to weigh against a stalled process. The bid is non-binding and contingent on due diligence, board approval and financing, though Fund 1 says a definitive agreement would carry no financing condition. It also wants the October 12 poison pill waived so other holders can participate. Now the board must respond to a bidder it has publicly described as constructive — a real fork in the road for a leveraged, cash-strapped franchisor.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XPOF was trading at $4.48 on NYSE in the Trade & Services sector, with a market capitalization of approximately $219.7M. The 52-week trading range was $3.57 to $9.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XPOF - Latest Insights

XPOF
Nov 09, 2026, 4:43 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.74
Real-time Price: $4.65 info
Change: -$0.090 (-2%) info
Market Cap: $230.008M info
XPOF
Nov 05, 2026, 4:26 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.05
Real-time Price: $4.65 info
Change: +$0.600 (+15%) info
Market Cap: $230.008M info
XPOF
Nov 05, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.42
Real-time Price: $4.65 info
Change: +$0.230 (+5%) info
Market Cap: $230.008M info
XPOF
Oct 20, 2026, 6:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $4.39
Real-time Price: $4.65 info
Change: +$0.260 (+6%) info
Market Cap: $230.008M info
XPOF
Oct 13, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.94
Real-time Price: $4.65 info
Change: -$0.290 (-6%) info
Market Cap: $230.008M info